Scienture Holdings, Inc. SCNX
information included in this Annual Report should be read in conjunction with the consolidated financial statements and related notes
in "Item 8. Financial Statements and Supplemental Data" of this Annual Report.
logo and some of our trademarks and tradenames are used in this Annual Report. This Annual Report may also include trademarks, tradenames
and service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this
Last close
2.88
2026-10-23
Market cap
$118.3M
2026-06-30 share count
52-week range
0.13 - 4.26
Valuation FY2025 figures against the last close
P/S274.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.70
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $431.6K | $136.6K | $1.4M | $10.3M | $9.9M | $17.1M | $7.4M | $3.8M | $2.9M | $2.5M |
| Cost of revenue | $100.1K | $130.6K | $1.3M | $4.7M | $5.1M | $11.4M | $2.6M | $449.0K | — | $16.4K |
| Gross profit | $331.5K | $6.0K | $49.0K | $5.5M | $4.7M | $5.7M | $4.9M | $3.4M | $2.9M | $2.5M |
| R&D | $2.0M | $2.2M | — | — | — | — | — | — | — | — |
| SG&A | $7.9M | $6.7M | $1.3M | $1.7M | $1.9M | $7.5M | $4.4M | $3.5M | $2.5M | $3.5M |
| Total operating expenses | $42.9M | $14.7M | $4.4M | $8.4M | $10.0M | $8.2M | $4.7M | $3.5M | — | — |
| Operating income | -$42.6M | -$14.7M | -$4.4M | -$2.9M | -$5.3M | -$2.5M | $125.2K | -$87.6K | $395.1K | -$1.0M |
| Interest expense | $4.1M | $1.3M | $1.1M | $336.2K | $23.6K | $29.4K | $53.2K | $57.5K | $157.1K | $151.5K |
| Pre-tax income | -$43.5M | -$18.8M | -$8.5M | — | — | — | — | — | — | — |
| Income tax | $2.0M | $534.4K | — | — | — | — | — | — | — | — |
| Net income | -$41.5M | $9.1M | -$17.8M | -$3.5M | -$5.3M | -$2.5M | -$284.4K | $9.0K | $289.0K | -$2.8M |
| EPS, basic | -2.70 | 2.69 | -23.35 | -6.15 | -0.65 | — | -0.05 | 0.00 | 0.01 | -0.09 |
| EPS, diluted | -2.70 | 2.48 | -23.35 | -6.13 | -0.65 | -0.33 | -0.05 | 0.00 | 0.01 | -0.09 |
| Shares, diluted (wtd. avg.) | 15.3M | 3.7M | 2.4M | 566,609 | 8.1M | — | 5.9M | 5.8M | 34.1M | 31.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.7M | — | $151.9K | $1.1M | $3.1M | $5.9M | $2.9M | $869.6K | $183.9K | $14.7K |
| Receivables | $731.3K | $11.1K | $821.8K | $629.9K | $979.0K | $805.0K | $792.0K | $433.6K | $319.5K | $299.1K |
| Inventory | $213.4K | — | $968 | $65.5K | $56.3K | $1.3M | $56.8K | $80.0K | — | — |
| Total current assets | $7.9M | $6.3M | $2.8M | $2.1M | $4.4M | $9.2M | $3.8M | $1.5M | $607.5K | $337.1K |
| Property, plant and equipment | $15.5K | $17.5K | $7.5K | $65.2K | $98.8K | $162.4K | $175.0K | $15.0K | — | — |
| Goodwill | — | $21.4M | — | $0 | $0 | — | $726.0K | $726.0K | — | — |
| Other intangibles | $71.0M | $76.4M | $9.0M | — | $792.0K | — | — | — | — | — |
| Total assets | $84.2M | $104.9M | $12.5M | $3.7M | $5.8M | $9.8M | $5.6M | $2.2M | $617.5K | $337.1K |
| Accounts payable | $1.4M | $2.9M | $1.5M | $528.0K | $477.0K | $256.8K | $334.6K | $400.5K | $106.1K | $236.8K |
| Total current liabilities | $2.7M | $7.9M | $11.6M | $2.1M | $926.0K | $842.2K | $520.8K | $860.4K | $525.4K | $1.5M |
| Long-term debt | — | $2.9M | — | — | — | — | $225.0K | $522.1K | $666.5K | — |
| Total liabilities | $14.1M | $25.8M | $12.0M | $3.4M | $2.0M | $1.1M | $1.4M | $1.4M | $929.4K | $1.5M |
| Retained earnings | -$80.6M | -$39.0M | -$33.2M | -$19.7M | -$16.2M | -$10.9M | -$8.4M | -$8.1M | -$8.1M | -$8.4M |
| Total equity | $70.1M | $79.1M | $542.4K | $342.9K | $3.8M | $8.7M | $4.1M | $844.7K | -$311.9K | -$1.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.4M | -$14.3M | -$2.2M | -$199.0K | -$2.6M | -$2.2M | $141.8K | $273.4K | $171.7K | -$503.5K |
| Depreciation and amortisation | $2.0K | $2.0K | $19.4K | $13.5K | $7.4K | $5.5K | $5.0K | — | $13.0K | $0 |
| Stock-based compensation | $2.1M | $25.6K | $29.7K | $79.2K | $64.2K | $448.4K | $176.4K | — | — | — |
| Capital expenditure | — | $12.0K | — | — | $22.6K | $37.5K | — | — | — | — |
| Investing cash flow | — | $27.6M | -$275.7K | $749 | -$22.6K | -$37.5K | -$332.3K | -$265.3K | $0 | -$78.0K |
| Financing cash flow | $19.7M | -$13.0M | $1.4M | $239.8K | -$208.2K | $5.3M | $2.2M | $677.5K | -$2.4K | $621.4K |
| Dividends paid | — | $2.2M | $12.7M | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020707.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.9M | $3.8M | $7.4M | $17.1M | $9.9M | $10.3M | $1.4M | $136.6K | $431.6K |
| Gross profit | $2.5M | $2.9M | $3.4M | $4.9M | $5.7M | $4.7M | $5.5M | $49.0K | $6.0K | $331.5K |
| Net income | -$2.8M | $289.0K | $9.0K | -$284.4K | -$2.5M | -$5.3M | -$3.5M | -$17.8M | $9.1M | -$41.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |